The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response
Author information
1University of California San Diego, La Jolla, CA 92093 USA.
2Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, Inserm 1110 and Université de Strasbourg, Strasbourg, France.
3Fundacion de Investigacion de Diego, San Juan, Puerto Rico.
4Beth Israel Deaconess Medical Center, Boston, MA, 02215 USA.
5Alamo Medical Research, San Antonio, TX 78215 USA.
6Gilead Sciences, Inc, Foster City, CA 94404 USA.
7Johns Hopkins University School of Medicine, Baltimore, MD 21287 USA.
Abstract
We measured IP-10 levels in 428 patients at baseline, week 1 and week 2 of all-oral HCV treatment. Increased baseline IP-10 was associated with a "T" allele in the IL28B gene, increased ALT in treatment-naïve but not experienced patients, and increased BMI. At week 1 the mean decline in plasma IP-10 levels was the same in treatment-naïve and -experienced patients (-49%), whereas during week 2 the mean decline in IP-10 levels in treatment-naïve patients (-14%) was significantly larger than in treatment-experienced patients (-2%) (p=0.0176). IP-10 thus may be a surrogate marker of the rate of intracellular viral replication complex decay.